Source comparison
Comparison Table: MK-677 Gene Expression Across Pathways
The following table summarizes the key transcriptional changes induced by mk-677 gene expression modulation, organized by signaling pathway and functional outcome. IGF-1/PI3K/Akt PPARGC1A (PGC-1α), HIF1A, MYC IGFBP1 (IGF binding protein-1) Increased mitochondr
This comparison does not assign a generated winner or score.
- The following table summarizes the key transcriptional changes induced by mk-677 gene expression modulation, organized by signaling pathway and functional outcome.
- IGF-1/PI3K/Akt
- PPARGC1A (PGC-1α), HIF1A, MYC
- IGFBP1 (IGF binding protein-1)
- Increased mitochondrial biogenesis, angiogenesis, cellular proliferation
- 24–72 hours
- This is the primary driver of MK-677's metabolic and performance effects. The upregulation is sustained with daily dosing
- mTORC1 Activation
- RPS6, EIF4E, SREBF1, FASN
- MSTN (myostatin), AMPK (during fed state)
- Enhanced protein synthesis, ribosomal biogenesis, de novo lipogenesis
- 6–12 hours
- The lipogenic signal can cause transient insulin resistance. Mitigate with low-carb intake during the first 2 weeks
- FOXO3a Suppression
- None (suppression pathway)
- SOD2, CAT, ATG7, BIM
- Reduced autophagy, oxidative stress defense, apoptosis of damaged cells
- 4–8 hours
- This is why cycling is critical. Continuous suppression beyond 12 weeks may impair cellular quality control mechanisms
- GH-Mediated (direct)
- IGF1 (hepatic), GHRH receptor
- SOCS2 (suppressor of cytokine signaling)
- Sustained elevation of circulating IGF-1, positive feedback on GH sensitivity
- 48–96 hours
- The pulsatile GH release pattern preserves physiological feedback loops better than exogenous GH administration
- Metabolic Adaptation
- GLUT4, LDLR, PPARA
- G6PC (glucose-6-phosphatase), PCK1 (PEPCK)
- Improved glucose uptake, enhanced fatty acid oxidation, reduced hepatic glucose output
- 1–2 weeks
- These adaptations require consistent dosing. Single doses produce minimal metabolic gene changes